Where is ViAqua located?

ViAqua is headquartered in Rehovot, Israel.

Who is the current CEO of ViAqua?

Shai Ufaz of ViAqua. They have also founded 1 company.

How many employees does ViAqua have?

As of May 31, 2026, the latest employee count at ViAqua is 14.

Is ViAqua a funded company?

ViAqua is a funded company, having raised a total of $12.5M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of ViAqua?

ViAqua's latest funding was a $***** Series A round on Sep 05, 2023, with participation from 4 investors.

Where does ViAqua rank among its competitors?

ViAqua ranks 12th amongst 183 active competitors, of which 57 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was NanoViricides, which secured $6M in Nov, 2025.

Who are the top competitors of ViAqua?

ViAqua's top competitors include Sirnaomics, Avadel Pharmaceuticals and NanoViricides. Among them, NanoViricides secured the most recent funding round in November, 2025.

ViAqua - 2026 Company Profile, Team, Funding & Competitors

ViAqua is a series A company based in Rehovot (Israel), founded in 2014 by Shai Einbinder and Shai Ufaz. It operates as a Developer of RNA-i formulated drug delivery technology for aquaculture. ViAqua has raised $12.5M in funding from S2G Investments and Nutreco. The company has 183 active competitors, including 57 funded and 15 that have exited. Its top competitors include companies like Sirnaomics, Avadel Pharmaceuticals and NanoViricides.

Company Details

Developer of RNA-i formulated drug delivery technology for aquaculture. The company has developed orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics. Its drug delivery platform uses proprietary RNAi nanoparticle formulation which is delivered via feed or immersion to produce and triggers a cell reaction to disable the viral infection.

Website: www.viaqua-t.com/
Email ID: *****@viaqua-t.com
Phone Number: +972 **********

Key Metrics

Founded Year

2014

Location

Rehovot, Israel

Stage

Series A

Total Funding

$12.5M in 6 rounds

Latest Funding Round

Series A, Sep 05, 2023, $*****

Investors

S2G Investments & 8 more

Ranked

12^th among 183 active competitors

Employee Count

14 as on May 31, 2026

Similar Companies

Sirnaomics & 219 more

View ViAqua's full profile

ViAqua has raised a total funding of $12.5M over 6 rounds. Its latest funding round was a Series A round on Sep 05, 2023 for $*****. 4 investors participated in its latest round. ViAqua has 9 institutional investors.

Here is the list of recent funding rounds of ViAqua:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2023	3084817	Series A	8155470	7016591	6586835	1525679
Jun 09, 2021	2972583	Series A	7461125	6444143	7457225	Thai Union Group & 6 more
Dec 13, 2018	2050293	Series A	6440618	4607676	4084094	Clay Capital

Access funding benchmarks and valuations. Sign up today!

View details of ViAqua's funding rounds and investors

The founders of ViAqua are Shai Einbinder and Shai Ufaz. Shai Ufaz is the CEO of ViAqua.

Here are the details of ViAqua's key team members:

Shai Einbinder: Co-Founder of ViAqua.
Shai Ufaz: Co-Founder & CEO of ViAqua.

View details of ViAqua's Founder profiles and Board Members

ViAqua's employee count trend

ViAqua has 14 employees as of May 26. Here is ViAqua's employee count trend over the years:

Uncover ViAqua's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ViAqua include Sirnaomics, Avadel Pharmaceuticals and NanoViricides. Here is the list of Top 10 competitors of ViAqua, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	63/100
2nd	Avadel Pharmaceuticals 1990, Dublin (Ireland), Acquired	Pharma company with proprietary drug delivery tools and drug for narcolepsy	-	Venrock, RTW Investments & 4 others	59/100
3rd	NanoViricides 2005, West Haven (United States), Public	Targeted antiviral therapeutics	-	-	59/100
4th	BioSapien 2018, New York City (United States), Seed	Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents	$10.6M	JPIN, Global Ventures & 13 others	58/100
5th	Splice Bio 2020, Barcelona (Spain), Series B	Provider of a proprietary platform for gene therapy	$192M	Ysios Capital, Sanofi Ventures & 9 others	58/100
6th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	56/100
7th	Midatech 2000, Abingdon (United Kingdom), Public	Provider of novel drug delivery technologies for the treatment of diseases	$16M	JDRF, Leonne International & 4 others	53/100
8th	Entos Pharmaceuticals 2016, Edmonton (Canada), Series A	Provider of nanotech-based drug delivery solutions	$1.1M	State of California, Canadian Space Agency ... & 3 others	52/100
9th	InnoMedica 2000, Bern (Switzerland), Acquired	Developer of therapeutics to treat cancer	$10.3M	-	51/100
10th	Amarna Therapeutics 2008, Leiden (Netherlands), Series A	Developer of immune-modulating gene therapies for rare and prevalent autoimmune diseases and genetic diseases	$11M	Flerie, Rijksdienst voor Ondernemend Nederland ... & 1 others	49/100
12th	ViAqua 2014, Rehovot (Israel), Series A	Developer of RNA-i formulated drug delivery technology for aquaculture	$12.5M	Nutreco, S2G Investments & 7 others	47/100